GSK data presented at ERS further supports its industry-leading respiratory medicines portfolio

GSK profiled the growing evidence base that supports its broad respiratory medicines portfolio at the European Respiratory Society (ERS) congress in Paris, France, 15-19 September 2018. Data presented in 50 abstracts will underscore the therapeutic value of key medicines across a spectrum of patients with asthma and chronic obstructive pulmonary disease (COPD).

?

Data presented will include new analyses from clinical studies across the medicines portfolio. These data provide evidence of the role different treatments have in optimising the management of respiratory diseases by addressing the main areas of individual patient need. Findings include the effect on exacerbations, or worsening of the condition, that many COPD and asthma patients suffer, as well as on lung function, symptoms such as breathlessness and quality of life. Data will also be presented assessing the benefit of treatments across disease severities and age groups.

?

Optimising COPD treatment???

New analyses of data from the landmark IMPACT study will help to clarify which patients can gain the greatest benefit from the different COPD combination treatment classes in the study, to provide further evidence on the right treatment for the right patient.

?

Building the evidence for targeted biologic therapy?

Development of the first-in-class anti-IL5 biologic Nucala (mepolizumab) represents a scientific innovation that is enabling a more targeted approach to the treatment of patients with severe eosinophilic asthma (SEA) and eosinophilic granulomatosis with polyangiitis (EGPA). In addition, Nucala is under investigation for patients with COPD, hypereosinophilic syndrome (HES) and nasal polyps.?Key presentations focus on the growing evidence assessing its role in the reduction of exacerbations across a range of age groups and disease severities in SEA.

?

In total, GSK presented data from 50 abstracts, including 13 oral presentations and 16 discussion and 21 thematic poster presentations.

?

?

Table of key abstracts:

Medicine

Title

Author

Presentation

Abstract /poster number

FF/UMEC/VI (GSK2834425)

Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial

Lipson DA, Barnhart F,
Boucot I, Crim C,
Brealey N, Criner G,
Dransfield M, Halpin D,
Kilbride S, Han MK,
Lange P, Lomas D,
Martinez FJ, Singh D,
Naya I, Jones CE,
Wise R

Thematic poster
COPD management
Tuesday 18th September 2018
12:50 - 14:40
TP-23
Session 444

PA4384

FF/UMEC/VI (GSK2834425)

Analysis of the InforMing the PAthway of COPD Treatment (IMPACT) study in the subgroup of patients taking triple therapy at screening

Singh D, Criner G,
Day NC, Dransfield M, Halpin DMG, Han MK,
Jones CE, Kilbride S,
Lange P, Lipson DA,
Lomas DA, Pascoe S,
Tabberer T, Wise R,
Martinez FJ

Oral presentation
COPD: from LABA/ICS to LABA/LAMA/ICS
Monday 17th September 2018
10:45 - 12:45 (Presentation time 11:45 - 12:00)
7.3Z2
Session 244

OA2129

FF/UMEC/VI (GSK2834425)

Blood eosinophil counts and treatment response in COPD: analyses of IMPACT

Pascoe S, Barnes N, Brusselle G, Compton C, Criner G, Dransfield M, Halpin DMG, Han MK,
Hartley B, Hilton E, Lange P, Lettis S, Lipson DA,
Lomas D, Martinez FJ,
Papi A, Roche N, van der Valk RJP, Wise R, Singh D

Oral presentation
COPD: from LABA/ICS to LABA/LAMA/ICS
Monday 17th September 2018
10:45 - 12:45 (Presentation time 11:15 - 11:30)
7.3Z2
Session 244

OA2127

FF/UMEC/VI (GSK2834425)

Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: Pre-specified analysis on lung function and health status from the IMPACT trial

Lipson DA, Barnhart F, Criner G, Wise R,
Lomas D, Halpin D,
Lange P, Brealey N, Dransfield M, Kilbride S, Martinez FJ, Singh D, Boucot I, Naya I, Han M, Jones CE, Crim C

Thematic poster
COPD management
Tuesday 18th September 2018
12:50 - 14:40
TP-23
Session 444

PA4385

mepolizumab (SB240563)

Mepolizumab for severe eosinophilic asthma: a comparison of efficacy in children, adolescents, and adults

Gupta A, Steinfeld J,
Price R, Azmi J, Bradford E, Yancey S

Poster discussion
New developments in paediatric asthma
Wednesday 19th September 2018
10:45 - 12:45
7.2B
Session 557

PA5447

mepolizumab (SB240563)

Long-term safety & durability of mepolizumab in life-threatening/seriously debilitating severe eosinophilic asthma (SEA): COSMEX

Albers F, Khurana S, Bradford E, Gilson M,
Price R, Brusselle G, Bel E, Fitzgerald M, Masoli M, Korn S, Humbert M

Oral presentation
Notable Studies in Asthma
Tuesday 18th September 2018
08:30 - 10:30 (Presentation time: 08:45 - 09:00)
7.3Z2
Session 379

OA3566

mepolizumab (SB240563)

Eosinophils as predictor of mepolizumab treatment responses in COPD

Pavord I, Criner G, Kerstjens H, Bradford E, Harris S, Keene O, Mayer B, Rubin D, Yancey S,
Bratton D

Poster discussion
Integrating pharmacological and non-pharmacological management in COPD: are we there yet?
Monday 17th September 2018
08:30 - 10:30
7.2A
Session 225

PA1992

mepolizumab (SB240563)

Immunogenicity of Mepolizumab in Patients with Severe Eosinophilic Asthma: Experience from the Clinical Development Program

Ortega H, Meyer E, Brusselle G, Asano K,

Price R, Prazma C,

Albers F, Yancey S,

Gleich G

Oral presentation

Novel immunology-based therapies in asthma and COPD

Sunday 16th September 2018

14:45 - 16:45 (Presentation time: 15:45 - 16:00)

7.3O

Session 176

OA1650

umeclidinium/vilanterol trifenatate (GSK2592356)

Economic and quality of life consequences of clinically important deterioration in patients with COPD: Results from the TORCH Study

Naya I, Driessen M,

Gunsoy N, Ismaila A, Risebrough N, Paly V, Briggs A

Oral Presentation

Clinical trials in COPD: new results

Sunday 16th September 2018

14:45 - 16:45 (Presentation time: 16:15 - 16:30)

7.3P

Session 177

OA1660

ambrisentan (GSK1325760)

Early improvements predict outcomes in pulmonary arterial hypertension

White RJ, Hoeper MM,

Blair C, Langley J,

Vizza CD

Oral Presentation

Risk stratification in treatment of pulmonary arterial hypertension

Sunday 16th September 2018

08:30 - 10:30 (Presentation time: 09:00 - 09:15)

7.3B

Session 47

OA269

?

GSK in China with China for China

GSK is committed to supporting the healthcare reform of the Chinese government and to ensuring that Chinese patients can access our innovative treatments targeting their specific needs. As part of our strategy to be "in China, with China, for China", we have achieved the following milestones in recent years:

?

  • Announced dual bronchodilators Anoro launched in China in Aug 2018, providing long-term, once-daily medication for COPD.
  • Dolutegravir recommended by WHO as the preferred first-line AIDS treatment in latest guidelines in Aug 2018.
  • Announced to aid China government’s hepatitis prevention and treatment programme in Jul 2018.
  • Cervarix is approved for cervical cancer prevention in female population aged 9-45 years in May 2018.
  • Announced Flixotide Nebules launched in mainland China for acute exacerbations of childhood asthma in May 2018.
  • The Chinese Association of STD and AIDS Prevention and Control and GSK China sign MOU for AIDS prevention and control through online physician education in May 2018.
  • GSK China partners with JD to drive “Internet + Healthcare” to improve patient experience and access to healthcare in May 2018.
  • Anoro Ellipta, a new once-daily dual bronchodilators treatment for COPD, was approved in March 2018.
  • Announced innovative antiretroviral Single Tablet Regimen Triumeq was officially launched in January 2018.

?

?

?

GSK – a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com.

?

?

GSK enquiries:

Chloe Yao??????? chloe.x.yao@gsk.com ? ??????????? (China)

Susan Song???? susan.s.song@gsk.com ?????????? (China)